Amylyx Pharmaceuticals

Focus: Amylyx is a neurology-focused specialty pharma company built on a single marketed product (RELYVRIO) combining two existing drugs for rare metabolic disorders. The company generates 100% of revenue from RELYVRIO, indicating a high-risk, single-asset dependency model.

Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Open Jobs

About Amylyx Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Amylyx Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RELYVRIO

Urea cycle disorder (neonatal and late-onset deficiency)

$198M Part D

Peak

Help build intelligence for Amylyx Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Commercializing a $198M Part D revenue-generating drug with peak lifecycle status and LOE protection until 2040 — rare opportunity for stability in rare disease
Pipeline diversification into ALS (AMX0035 Phase 3 with 10 trials, AMX0114 Phase 1) and post-bariatric hypoglycemia (Avexitide Phase 3) reduces single-asset risk medium-term
Cambridge biotech location with neurology expertise attracts top clinical and regulatory talent competing for rare disease development experience

Watch Out For

Zero active job openings signals hiring freeze or contraction risk despite $198M in annual revenue — growth trajectory unclear
100% revenue concentration on one drug creates existential risk if RELYVRIO faces safety signals, label restrictions, or reimbursement pressure before pipeline matures
Limited public visibility into R&D spend, employee count, and cash position — financial health and runway opacity makes career continuity unpredictable

Pipeline & Clinical Trials

AMX0114

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Phase 1

AMX0035

Amyotrophic Lateral Sclerosis

Phase 3

Clinical Trials (5)

NCT05619783Extension Study Evaluating The Safety And Tolerability of AMX0035

Phase 3

NCT05021536Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Phase 3

Avexitide

Post-Bariatric Hypoglycemia

Phase 3

Clinical Trials (1)

NCT06747468Avexitide for Treatment of Post-Bariatric Hypoglycemia

Phase 3

Amylyx Pharmaceuticals

About Amylyx Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)